» Articles » PMID: 23533650

Neutralizing Antibody Responses in Macaques Induced by Human Immunodeficiency Virus Type 1 Monovalent or Trivalent Envelope Glycoproteins

Overview
Journal PLoS One
Date 2013 Mar 28
PMID 23533650
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

A major goal of efforts to develop a vaccine to prevent HIV-1 infection is induction of broadly cross-reactive neutralizing antibodies (bcnAb). In previous studies we have demonstrated induction of neutralizing antibodies that did cross-react among multiple primary and laboratory strains of HIV-1, but neutralized with limited potency. In the present study we tested the hypothesis that immunization with multiple HIV-1 envelope glycoproteins (Envs) would result in a more potent and cross-reactive neutralizing response. One Env, CM243(N610Q), was selected on the basis of studies of the effects of single and multiple mutations of the four gp41 glycosylation sites. The other two Envs included R2 (subtype B) and 14/00/4 (subtype F), both of which were obtained from donors with bcnAb. Rhesus monkeys were immunized using a prime boost regimen as in previous studies. Individual groups of monkeys were immunized with either one of the three Envs or all three. The single N610Q and N615Q mutations of CM243 Env did not disrupt protein secretion, processing into, or reactivity with mAbs, unlike other single or multiple deglycosylation mutations. In rabbit studies the N610Q mutation alone or in combination was associated with an enhanced neutralizing response against homologous and heterologous subtype E viruses. In the subsequent monkey study the response induced by the R2 Env regimen was equivalent to the trivalent regimen and superior to the other monovalent regimens against the virus panel used for testing. The 14/00/4 Env induced responses superior to CM243(N610Q). The results indicate that elimination of the glycosylation site near the gp41 loop results in enhanced immunogenicity, but that immunization of monkeys with these three distinct Envs was not more immunogenic than with one.

Citing Articles

New prospects for a preventive HIV-1 vaccine.

Brown J, Excler J, Kim J J Virus Erad. 2015; 1(2):78-88.

PMID: 26523292 PMC: 4625840.


Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Kilgore K, Murphy M, Burton S, Wetzel K, Smith S, Xiao P J Virol. 2015; 89(16):8130-51.

PMID: 26018167 PMC: 4524250. DOI: 10.1128/JVI.01221-14.


Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.

Carbonetti S, Oliver B, Glenn J, Stamatatos L, Sather D PLoS One. 2014; 9(1):e86905.

PMID: 24466285 PMC: 3900663. DOI: 10.1371/journal.pone.0086905.

References
1.
Mascola J . Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine. 2002; 20(15):1922-5. DOI: 10.1016/s0264-410x(02)00068-3. View

2.
Dong M, Zhang P, Grieder F, Lee J, Krishnamurthy G, VanCott T . Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol. 2003; 77(5):3119-30. PMC: 149731. DOI: 10.1128/jvi.77.5.3119-3130.2003. View

3.
Zwick M, Kelleher R, Jensen R, Labrijn A, Wang M, Quinnan Jr G . A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J Virol. 2003; 77(12):6965-78. PMC: 156200. DOI: 10.1128/jvi.77.12.6965-6978.2003. View

4.
Thali M, Furman C, Ho D, Robinson J, Tilley S, Pinter A . Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol. 1992; 66(9):5635-41. PMC: 289129. DOI: 10.1128/JVI.66.9.5635-5641.1992. View

5.
Ruprecht R, Hofmann-Lehmann R, Rasmussen R, Liska V, Vlasak J, Xu W . Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus Clin Biol. 2001; 8(4):350-8. DOI: 10.1016/s1246-7820(01)00187-2. View